Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists Fine-Tune Clot-Busting drug for brain hemorrhage in the lab

NCT ID NCT07411079

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study uses blood samples from over 1,100 people to create artificial clots in the lab, mimicking brain hemorrhages. Researchers test a modified clot-busting drug (rtPA) to find the best dose for different bleeding risks. The goal is to improve clot removal and guide future treatments for this serious condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
modified tissue plasminogen activator (rtPA)
What this could lead to
If successful, this could lead to personalized dosing of clot-busting drugs for brain hemorrhage patients, potentially improving clot removal and reducing disability.
What could go wrong
This is an early lab study using artificial clots, not real patients. Results may not translate to actual treatment, and the drug's safety and effectiveness in people remain unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,126 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults receiving routine outpatient care who are either without hemorrhagic risk or have predefined hemorrhagic risk profiles, including antithrombotic treatment, inherited bleeding disorders, thrombocytopenia, or conditions requiring reversal or correction of coagulation abnormalities, and who consent to a single blood sample collection.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult participants (≥ 18 years of age) * Able and willing to provide written informed consent * Receiving routine outpatient care * Either: * Without identified hemorrhagic risk (control subjects) * With a predefined hemorrhagic risk profile, including antithrombotic treatment, inherited bleeding disorders, thrombocytopenia or conditions requiring reversal or correction of coagulation abnormalities * Able to undergo a single additional whole blood collection (30 mL) during a routine clinical visit Exclusion Criteria: * Age \< 18 years * Inability or unwillingness to provide written informed consent * Contraindication to venipuncture or blood sampling * Known human immunodeficiency virus (HIV) infection * Breastfeeding * Presence of an additional coagulation abnormality not related to the identified hereditary bleeding disorder or the antithrombotic treatment under study * Individuals deprived of liberty by judicial or administrative decision * Individuals under legal protection (guardianship or curatorship)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bleeding disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hemorrhagic disease intracerebral hemorrhage Intracranial Hemorrhages vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bleeding disorders Hemorrhagic risk conditions Intracerebral hemorrhage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Lille

    RECRUITING

    Lille, 59000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.